medigraphic.com
Patología Revista Latinoamericana

2011, Number 2

<< Back Next >>

Patol Rev Latinoam 2011; 49 (2)

From the plasma cell to multiple myeloma: a brief historical perspective

Ortiz HC

Language: Spanish
References: 54
Page: 120-131
PDF size: 662.82 Kb.


ABSTRACT

In a series of articles published between 1844 and 1850, Solly, Dalrymple, Bence-Jones and Macintyre described the essential features of the disease then known as “Molleties ossium” and later named by von Rustizky as multiple myeloma. In 1889 Otto Kahler described a patient with progressive bone pain and proteinuria and at autopsy he found large, rounded cells, consistent with multiple myeloma. Ramon y Cajal described in 1890 the plasma cell (the cyanophile cells of Cajal), Waldeyer called them Plasmazellen and Marschalkó described its mature characteristics. In 1900 Homer-Wright in an autopsy case of a 54 year of patient, described the cell origin of multiple myeloma. Bayne-Jones and Wilson in 1922 first found two distinct groups of Bence-Jones proteins and in 1956 the relationship between Bence- Jones proteins and the serum proteins of multiple myeloma was demonstrated by Kongord and Lipari. Edelman and Gally demonstrated in 1962, that the light chains from serum IgG myeloma protein and the Bence-Jones proteins were identical. While multiple myeloma has been known for over 100 years, much has been learned about the cell origin, its pathogenesis, molecular biology, and treatment; however, its cause is still an enigma.


REFERENCES

  1. Kyle RA. Multiple myeloma: An odyssey of discovery. Br J Haematol 2000;111:1035-1044.

  2. Kyle RA. Multiple myeloma: how did it begin? Mayo Clin Proc 1994;69;680-683. Figura 6. Página frontal y algunas de las ilustraciones originales realizadas por William Russell en 1899 (cuerpos fucsinofílicos de Russell).

  3. Perrin TG. Contribución al estudio de los plasmocitomas. Un caso de fibroplasmocitoma osteógeno. Gac Med Mex 1925;56;409-415.

  4. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, et al. WHO Classification of Tumors of Hematopoyetic and Lymphoid Tissues. 4th ed. Lyon; 2008:200-213.

  5. Lin P. Plasma cell myeloma. Hematol Clin N A 2009;23:709-727.

  6. Kyle RA, Rajkumar SV. Multiple myleoma. Blood 2008;111;2962-2972.

  7. Bladé J, Dimopoulos M, Rosiñol L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome and follow-up recommendations J Clin Oncol 2010;28:690-697. Epub 2009Dec 21.

  8. Morse D, Dailey RC, Baunn J. Prehistoric multiple myeloma. Bull N Y Acad Med 1974;50;447-458.

  9. Clamp JR. Some aspects of the first recorded case of multiple myeloma. Lancet 1967;23;1354-1356.

  10. Kyle RA. Five decades of therapy for multiple myeloma: a paradigm for therapeutic. Leukemia 2005;19:910-912.

  11. Díaz-Maqueo JC. Historia del mieloma. Rev Biomed 2006;17:225-229.

  12. Schleicher EM. Plasma cell. 100 year anniversary; a brief chronology. Minnesotta Medicine; 1977;60:131-133.

  13. Anaya A, Ramón y Cajal Junquera S, Langa MA. Las células cianófilas de Cajal. Rev Esp Patol 2002;35:233-237.

  14. Jiménez de Asúa F. Células cianófilas y células cebadas (Plasmazellen y Mastzellen) 1ª parte. Bol de la Real Sociedad Esp de Historia Natural 1922;22:115-121.

  15. Cervos-Navarro J. Cajal en Europa. Rev Esp Patol 2002;35:481-486.

  16. Ramón y Cajal S. Estudios histológicos sobre los tumores epiteliales. Rev Trim Microgr 1891:8-96.

  17. Wright JH. A case of multiple myeloma. J Boston Soc Med Sci 1900;4:195-204.

  18. Lee RE. James Homer Wright. A biography of the enigmatic creator of Wright Stain on the occasion lf its centennial. Am J Surg Pathol 2002;26:88-96.

  19. Pearce JMS A note on scrivener’s palsy. Samuell Solly (1805-1817). J Neurol Neurosurg Psychiatry 2005;76:513.

  20. Solly S. Remarks on the pathology of mollities ossium with cases. Med Chir Trans Lond 1844;27:435-461.

  21. Macintyre W. Case of mollities and fragilitas ossium. Royal Med and Chir Society 1850;33;211-232.

  22. Rosenfeld L. Henry Bence Jones (1813-1873): The best chemical doctor in London. Clin Chem 1987;33:1687-1692.

  23. Kyle RA. Henry Bence Jones- Physician, chemist scientist and biographer. A man of all seasons. Br J Hematol 2001;115:13-18.

  24. Stone MJ. Henry Bence Jones and his protein. J Med Biog 1998;6:53-57.

  25. Bence Jones H. On a new substance occurring in the urine of a patient with moilleties ossium. Phil Trans Roy Soc of London. Series B Biological Science 1848;138:55-62.

  26. Bence Jones H. Chemical Pathology, Lecture III. Lancet 1847;2:88-92.

  27. Hajdu SI. A note form History: The first biochemical test for detection of Cancer. Ann Clin Lab Sci 2006;36;222-223.

  28. Dalrymple J. On the microscopic character of mollities ossium. Dublin Quarterly J Med Sci 1846;2:85-95.

  29. Von Rustizky J. Multiples myelom. Dtsch Z Chir 1873;3:162-172.

  30. Kahler O. Zur symptomatologie des multiplen myeloms. Wiener Medizinische Presse 1889;30:209-213.

  31. Bayne-Jones S, Wilson DW. Immunological reactions of Bence-Jones proteins: II differences between Bence-Jones proteins from various sources. Bull Johns Hopkins Hos 1922;33:119-125.

  32. Korngold L, Lipiari R. Multiple myeloma proteins III. The antigenic relationship of Bence Jones protein to normal gamma-globulin and multiple myeloma serum proteins Cancer 1956;9:262-272.

  33. Edelman GM. Antibody structure and molecular immunology (1972 Nobel Prize Address) Science 1973;180:830-839.

  34. Porter R. Structural studies of immunoglobulins (1972 Nobel Prize Address) Science 1973;180:713-716.

  35. Tiselius AWK. A new apparatus for electrophoretic analysis of colloidal mixtures. Trans Faraday Soc 1937; 33:524-531.

  36. Longsworth LG, Shedlovsky T, Macinnes DA. Electrophoretic patterns of normal and pathological human blood, serum, and plasma. J Exp Med 1939;70:399-413.

  37. Merlini G. In memory of Jan Waldenström. Obituary. Haematologica 1997;82:255-256.

  38. Lichtman MA, Spivak JL, Boxer LA, Shattil SJ, Henderson ES. Commentary: Waldenstöm J (1944): Incipient myelomatosis or “essential hyperglobulinemia with fibrinogenopenia” –a new syndrome? Acta Medica Scand 117;216-247. En: Hematology. Landmark papers of the twentieth century. San Diego: Academic Press; 2000:227-228. Landmark papers in Hematology

  39. Waldenström J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect 1961;56:211-231.

  40. Rajkumar SV. MGUs and smoldering multiple myeloma; Update on pathogenesis, natural history and management. Hematology (Am Soc Hematol Educ Program) 2005:340-345.

  41. Dutcher TF, Fahey JL. The histopathology of macroglobuiemia of Waldenström. J Natl Cancer Inst 1959;22:887-917.

  42. Bain BJ. Dutcher bodies. Am J Hematol 2009;84:589.

  43. Russell W. An address on the characteristic organism of cancer. Br Med J 1890;2:1356-1360.

  44. King DF. Russell’s fuchsine body. The characteristic organism of cancer. Am J Dermatopathol 1981;3:55-58.

  45. Russell W. The parasite of cancer. Lancet 1899;1:1138-1141.

  46. Cantwell A. The Russell body. The forgotten clue to the bacterial cause of cancer. J Indep Med Res 2003;1:1-8.

  47. Mott FW. Observations on the Brains of men and animals infected with various forms of Trypanosomes: preliminary note. Proc R Soc Lond B 1905;76:235-242.

  48. Singhal S, Mehta J, Desikan R, Ayers D, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.

  49. Ciechanover A The ubiquitin system: historical perspective. Proc Am Thorac Soc 2010;7:11-22.

  50. Chng WJ, Glebov O, Bergsael PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Prac Res Clin Hematol 2007;20:571-596.




2020     |     www.medigraphic.com